Dapagliflazocin therapy in chronic kidney disease ( CKD )

The management of Chronic Kidney Disease (CKD) is an evolving field, enriched by emerging clinical trials and treatment modalities. One of the most recent additions to this repertoire is Dapagliflozin, an oral treatment option that has shown promise in clinical studies. This introduction serves to preface a concise table outlining the key recommendations and rationale for the use of Dapagliflozin in the treatment of CKD. The table delineates the specific conditions under which this medication is recommended, the prerequisites regarding estimated Glomerular Filtration Rate (eGFR) and urine Albumin-to-Creatinine Ratio (uACR), as well as guidelines for existing treatments. This summary aims to offer a succinct, evidence-based reference for healthcare professionals in primary care as recommended by NICE, thereby aiding in informed clinical decision-making.

Recommendation Component	Guidelines and Rationale
Drug Recommendation	• Dapagliflozin is recommended as an option for treating adult CKD. • Clinical trials have shown its efficacy in slowing down CKD progression when added to standard care.
Treatment Conditions	♦ Dapagliflozin is recommended only if it is an add-on to optimised standard care including ACE inhibitors or ARBs (unless contraindicated). ♦ Standard care already incorporates ACE inhibitors or ARBs, and dapagliflozin is most effective as an adjunct to this treatment....

Try our Free Plan to get the full article.